Published in Eur J Neurosci on November 01, 2006
Anti-amyloid-beta immunotherapy in Alzheimer's disease: relevance of transgenic mouse studies to clinical trials. J Alzheimers Dis (2008) 2.01
Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci (2010) 1.97
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem (2011) 1.82
Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci (2010) 1.66
Alzheimer disease. Dis Mon (2010) 1.64
Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J Neurosci (2009) 1.59
Amyloid-beta immunisation for Alzheimer's disease. Lancet Neurol (2008) 1.38
Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res (2008) 1.32
Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies. J Alzheimers Dis (2008) 1.22
Inflammation in Alzheimer's disease: relevance to pathogenesis and therapy. Alzheimers Res Ther (2010) 1.20
Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta (2010) 1.14
Immunotherapeutic approaches for Alzheimer's disease. Neuron (2015) 1.13
Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS One (2010) 1.07
Amyloid-beta immunotherapy for Alzheimer's disease. CNS Neurol Disord Drug Targets (2010) 1.07
A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol Aging (2007) 1.06
Immunotherapy for Alzheimer's disease. Biochem Pharmacol (2014) 1.04
MER5101, a novel Aβ1-15:DT conjugate vaccine, generates a robust anti-Aβ antibody response and attenuates Aβ pathology and cognitive deficits in APPswe/PS1ΔE9 transgenic mice. J Neurosci (2013) 0.98
Immunotherapeutic approaches for Alzheimer's disease in transgenic mouse models. Brain Struct Funct (2009) 0.95
Blocking the apolipoprotein E/amyloid-β interaction reduces fibrillar vascular amyloid deposition and cerebral microhemorrhages in TgSwDI mice. J Alzheimers Dis (2011) 0.94
Immunomodulation targeting of both Aβ and tau pathological conformers ameliorates Alzheimer's disease pathology in TgSwDI and 3xTg mouse models. J Neuroinflammation (2013) 0.93
Anti-dementia drugs and hippocampal-dependent memory in rodents. Behav Pharmacol (2007) 0.93
Vaccination as a therapeutic approach to Alzheimer's disease. Mt Sinai J Med (2010) 0.92
Developing therapeutic vaccines against Alzheimer's disease. Expert Rev Vaccines (2015) 0.90
Antibody response and plasma Abeta1-40 levels in young Microcebus murinus primates immunized with Abeta1-42 and its derivatives. Vaccine (2008) 0.90
Blocking the apolipoprotein E/amyloid β interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid β and tau pathology. J Neurochem (2013) 0.87
Preventing beta-amyloid fibrillization and deposition: beta-sheet breakers and pathological chaperone inhibitors. BMC Neurosci (2008) 0.86
Amyloid β and Tau Alzheimer's disease related pathology is reduced by Toll-like receptor 9 stimulation. Acta Neuropathol Commun (2014) 0.85
Amyloid beta immunization worsens iron deposits in the choroid plexus and cerebral microbleeds. Neurobiol Aging (2013) 0.84
Harnessing the immune system for treatment and detection of tau pathology. J Alzheimers Dis (2014) 0.82
Immune complex formation impairs the elimination of solutes from the brain: implications for immunotherapy in Alzheimer's disease. Acta Neuropathol Commun (2013) 0.81
Linear and conformation specific antibodies in aged beagles after prolonged vaccination with aggregated Abeta. Neurobiol Dis (2010) 0.81
Immunomodulation for prion and prion-related diseases. Expert Rev Vaccines (2010) 0.80
Cognitive and sensorimotor tasks for assessing functional impairments in mouse models of Alzheimer's disease and related disorders. Methods Mol Biol (2012) 0.80
Could immunomodulation be used to prevent prion diseases? Expert Rev Anti Infect Ther (2012) 0.80
Diminished amyloid-beta burden in Tg2576 mice following a prophylactic oral immunization with a salmonella-based amyloid-beta derivative vaccine. J Alzheimers Dis (2009) 0.80
Comparative Safety of Vaccine Adjuvants: A Summary of Current Evidence and Future Needs. Drug Saf (2015) 0.79
AD vaccines: conclusions and future directions. CNS Neurol Disord Drug Targets (2009) 0.79
Specific amyloid β clearance by a catalytic antibody construct. J Biol Chem (2015) 0.76
Innate Immunity Stimulation via Toll-Like Receptor 9 Ameliorates Vascular Amyloid Pathology in Tg-SwDI Mice with Associated Cognitive Benefits. J Neurosci (2017) 0.75
The Cox-2 Inhibitor Meloxicam Ameliorates Neuroinflammation and Depressive Behavior in Adult Mice after Splenectomy. J Neurophysiol Neurol Disord (2016) 0.75
Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy. Mol Neurodegener (2016) 0.75
Sex and Immunogen-Specific Benefits of Immunotherapy Targeting Islet Amyloid Polypeptide in Transgenic and Wild-Type Mice. Front Endocrinol (Lausanne) (2016) 0.75
AMYLOID CLEARING IMMUNOTHERAPY FOR ALZHEIMER'S DISEASE AND THE RISK OF CEREBRAL AMYLOID ANGIOPATHY. Alzheimers Dis Res J (2007) 0.75
Antioxidant peroxiredoxin 6 protein rescues toxicity due to oxidative stress and cellular hypoxia in vitro, and attenuates prion-related pathology in vivo. Neurochem Int (2015) 0.75
Novel immunological approaches for the treatment of Alzheimer's disease. Zhongguo Xian Dai Shen Jing Ji Bing Za Zhi (2014) 0.75
Gene therapy targeting mitochondrial pathway in Parkinson's disease. J Neural Transm (Vienna) (2016) 0.75
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. Ann Neurol (2004) 21.56
Correlative memory deficits, Abeta elevation, and amyloid plaques in transgenic mice. Science (1996) 19.72
Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse. Nature (1999) 12.95
Neuropathology of human Alzheimer disease after immunization with amyloid-beta peptide: a case report. Nat Med (2003) 7.83
A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease. Nature (2001) 7.35
A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease. Nature (2001) 6.78
Age-dependent changes in brain, CSF, and plasma amyloid (beta) protein in the Tg2576 transgenic mouse model of Alzheimer's disease. J Neurosci (2001) 6.32
Clinical effects of Abeta immunization (AN1792) in patients with AD in an interrupted trial. Neurology (2005) 5.51
Stereological methods for estimating the total number of neurons and synapses: issues of precision and bias. Trends Neurosci (1999) 5.15
Immunization reverses memory deficits without reducing brain Abeta burden in Alzheimer's disease model. Nat Neurosci (2002) 5.01
The antigenic index: a novel algorithm for predicting antigenic determinants. Comput Appl Biosci (1988) 5.00
Characterization of progressive motor deficits in mice transgenic for the human Huntington's disease mutation. J Neurosci (1999) 4.56
Antibodies against beta-amyloid slow cognitive decline in Alzheimer's disease. Neuron (2003) 4.39
Cerebral hemorrhage after passive anti-Abeta immunotherapy. Science (2002) 3.93
Reversible memory loss in a mouse transgenic model of Alzheimer's disease. J Neurosci (2002) 3.20
Neuropathology and pathogenesis of encephalitis following amyloid-beta immunization in Alzheimer's disease. Brain Pathol (2004) 3.01
Abeta vaccination effects on plaque pathology in the absence of encephalitis in Alzheimer disease. Neurology (2005) 2.79
Passive immunotherapy against Abeta in aged APP-transgenic mice reverses cognitive deficits and depletes parenchymal amyloid deposits in spite of increased vascular amyloid and microhemorrhage. J Neuroinflammation (2004) 2.67
Aluminum compounds as vaccine adjuvants. Adv Drug Deliv Rev (1998) 2.36
Exacerbation of cerebral amyloid angiopathy-associated microhemorrhage in amyloid precursor protein transgenic mice by immunotherapy is dependent on antibody recognition of deposited forms of amyloid beta. J Neurosci (2005) 2.21
Anti-Abeta42- and anti-Abeta40-specific mAbs attenuate amyloid deposition in an Alzheimer disease mouse model. J Clin Invest (2005) 1.96
Immunization with a nontoxic/nonfibrillar amyloid-beta homologous peptide reduces Alzheimer's disease-associated pathology in transgenic mice. Am J Pathol (2001) 1.69
Prototype Alzheimer's disease vaccine using the immunodominant B cell epitope from beta-amyloid and promiscuous T cell epitope pan HLA DR-binding peptide. J Immunol (2005) 1.56
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol (2004) 1.50
An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci (2004) 1.43
Reduced effectiveness of Abeta1-42 immunization in APP transgenic mice with significant amyloid deposition. Neurobiol Aging (2001) 1.39
Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med (2003) 1.35
ELISA method for measurement of amyloid-beta levels. Methods Mol Biol (2005) 1.28
Tissue processing prior to protein analysis and amyloid-beta quantitation. Methods Mol Biol (2005) 1.28
Immunotherapy for Alzheimer's disease. Proc Natl Acad Sci U S A (2004) 1.17
Behavioural, histochemical and biochemical consequences of selective immunolesions in discrete regions of the basal forebrain cholinergic system. Neuroscience (1994) 1.15
A closed-field intelligence test for rats. Can J Psychol (1951) 1.13
A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol Aging (2007) 1.06
Demonstration of poly-N-acetyl lactosamine residues in ameboid and ramified microglial cells in rat brain by tomato lectin binding. J Histochem Cytochem (1994) 1.06
Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol (2005) 1.05
Local and distant histopathological effects of unilateral amyloid-beta 25-35 injections into the amygdala of young F344 rats. Neurobiol Aging (1997) 1.04
Motor learning in Ts65Dn mice, a model for Down syndrome. Dev Psychobiol (2001) 1.01
A method of rating animal intelligence. J Gen Psychol (1946) 1.01
The immune system, amyloid-beta peptide, and Alzheimer's disease. Immunol Rev (2005) 0.96
Lifelong immunization with human beta-amyloid (1-42) protects Alzheimer's transgenic mice against cognitive impairment throughout aging. Neuroscience (2005) 0.91
Meningoencephalitis associated with passive immunization of a transgenic murine model of Alzheimer's amyloidosis. FEBS Lett (2005) 0.90
Intracerebroventricular passive immunization with anti-Abeta antibody in Tg2576. J Neurosci Res (2003) 0.88
Histological staining of amyloid-beta in mouse brains. Methods Mol Biol (2005) 0.88
Immunotherapy for conformational diseases. Curr Pharm Des (2006) 0.87
Of mice and men: virtual Hebb-Williams mazes permit comparison of spatial learning across species. Cogn Affect Behav Neurosci (2001) 0.87
Amyloid-beta immunization in Alzheimer's disease transgenic mouse models and wildtype mice. Neurochem Res (2003) 0.84
Immunization therapy for Alzheimer disease? Neurology (2005) 0.81
RAGE mediates amyloid-beta peptide transport across the blood-brain barrier and accumulation in brain. Nat Med (2003) 5.14
Amyloid ion channels: a common structural link for protein-misfolding disease. Proc Natl Acad Sci U S A (2005) 3.91
A presenilin-1/gamma-secretase cleavage releases the E-cadherin intracellular domain and regulates disassembly of adherens junctions. EMBO J (2002) 3.87
Correlation of Alzheimer disease neuropathologic changes with cognitive status: a review of the literature. J Neuropathol Exp Neurol (2012) 3.77
Primary age-related tauopathy (PART): a common pathology associated with human aging. Acta Neuropathol (2014) 3.75
Immunotherapy targeting pathological tau conformers in a tangle mouse model reduces brain pathology with associated functional improvements. J Neurosci (2007) 3.10
A novel human disease with abnormal prion protein sensitive to protease. Ann Neurol (2008) 2.95
Alzheimer amyloid-β oligomer bound to postsynaptic prion protein activates Fyn to impair neurons. Nat Neurosci (2012) 2.92
Amyloid beta protein dimer-containing human CSF disrupts synaptic plasticity: prevention by systemic passive immunization. J Neurosci (2008) 2.77
A primer of amyloid nomenclature. Amyloid (2007) 2.70
The neuropathology of autism: defects of neurogenesis and neuronal migration, and dysplastic changes. Acta Neuropathol (2010) 2.42
FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease. Eur J Nucl Med Mol Imaging (2009) 2.15
Amyloid: toward terminology clarification. Report from the Nomenclature Committee of the International Society of Amyloidosis. Amyloid (2005) 2.14
Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model. J Neurosci (2010) 1.97
5-Lipoxygenase gene disruption reduces amyloid-beta pathology in a mouse model of Alzheimer's disease. FASEB J (2007) 1.97
Metabotropic glutamate receptor 5 is a coreceptor for Alzheimer aβ oligomer bound to cellular prion protein. Neuron (2013) 1.87
Blocking the apolipoprotein E/amyloid-beta interaction as a potential therapeutic approach for Alzheimer's disease. Proc Natl Acad Sci U S A (2006) 1.85
Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain. J Neurochem (2011) 1.82
The familial dementia BRI2 gene binds the Alzheimer gene amyloid-beta precursor protein and inhibits amyloid-beta production. J Biol Chem (2005) 1.67
Anti-PrPC monoclonal antibody infusion as a novel treatment for cognitive deficits in an Alzheimer's disease model mouse. BMC Neurosci (2010) 1.66
Induction of toll-like receptor 9 signaling as a method for ameliorating Alzheimer's disease-related pathology. J Neurosci (2009) 1.59
Amyloid fibril protein nomenclature -- 2002. Amyloid (2002) 1.59
Genetics and molecular pathogenesis of sporadic and hereditary cerebral amyloid angiopathies. Acta Neuropathol (2009) 1.57
Cerebral amyloid angiopathies: a pathologic, biochemical, and genetic view. J Neuropathol Exp Neurol (2003) 1.56
A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol (2004) 1.50
BRI2 interacts with amyloid precursor protein (APP) and regulates amyloid beta (Abeta) production. J Biol Chem (2005) 1.48
Dissolution of arterial platelet thrombi in vivo with a bifunctional platelet GPIIIa49-66 ligand which specifically targets the platelet thrombus. Blood (2010) 1.47
Ligand binding and calcium influx induce distinct ectodomain/gamma-secretase-processing pathways of EphB2 receptor. J Biol Chem (2007) 1.44
An attenuated immune response is sufficient to enhance cognition in an Alzheimer's disease mouse model immunized with amyloid-beta derivatives. J Neurosci (2004) 1.43
Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging. Neurobiol Dis (2002) 1.42
Physostigmine reverses cognitive dysfunction caused by moderate hypoxia in adult mice. Anesth Analg (2007) 1.38
MRI assessment of neuropathology in a transgenic mouse model of Alzheimer's disease. Magn Reson Med (2004) 1.37
Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging. Magn Reson Med (2003) 1.35
Sporadic and familial cerebral amyloid angiopathies. Brain Pathol (2002) 1.33
Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging. J Neurosci Res (2008) 1.32
Systemic catabolism of Alzheimer's Abeta40 and Abeta42. J Biol Chem (2004) 1.30
Binding of cystatin C to Alzheimer's amyloid beta inhibits in vitro amyloid fibril formation. Neurobiol Aging (2004) 1.27
Immunization delays the onset of prion disease in mice. Am J Pathol (2002) 1.26
Identification of distinct N-terminal truncated forms of prion protein in different Creutzfeldt-Jakob disease subtypes. J Biol Chem (2004) 1.26
Overexpression of wild type but not an FAD mutant presenilin-1 promotes neurogenesis in the hippocampus of adult mice. Neurobiol Dis (2002) 1.24
Clearance and prevention of prion infection in cell culture by anti-PrP antibodies. Eur J Neurosci (2006) 1.22
An aggregation-specific enzyme-linked immunosorbent assay: detection of conformational differences between recombinant PrP protein dimers and PrP(Sc) aggregates. J Virol (2005) 1.22
Familial Danish dementia: co-existence of Danish and Alzheimer amyloid subunits (ADan AND A{beta}) in the absence of compact plaques. J Biol Chem (2005) 1.18
Copper chelation delays the onset of prion disease. J Biol Chem (2003) 1.17
PART, a distinct tauopathy, different from classical sporadic Alzheimer disease. Acta Neuropathol (2015) 1.17
Axonal transport of British and Danish amyloid peptides via secretory vesicles. FASEB J (2003) 1.17
Familial Danish dementia: a novel form of cerebral amyloidosis associated with deposition of both amyloid-Dan and amyloid-beta. J Neuropathol Exp Neurol (2002) 1.16
The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease. Acta Neuropathol (2001) 1.15
Intraneuronal Abeta immunoreactivity is not a predictor of brain amyloidosis-beta or neurofibrillary degeneration. Acta Neuropathol (2007) 1.15
Amyloidosis and Alzheimer's disease. Adv Drug Deliv Rev (2002) 1.14
Murine models of Alzheimer's disease and their use in developing immunotherapies. Biochim Biophys Acta (2010) 1.14
Antibody uptake into neurons occurs primarily via clathrin-dependent Fcγ receptor endocytosis and is a prerequisite for acute tau protein clearance. J Biol Chem (2013) 1.12
Amyloid beta40/42 clearance across the blood-brain barrier following intra-ventricular injections in wild-type, apoE knock-out and human apoE3 or E4 expressing transgenic mice. J Alzheimers Dis (2001) 1.11
Cell type- and brain structure-specific patterns of distribution of minibrain kinase in human brain. Brain Res (2004) 1.11
Anti-prion antibodies for prophylaxis following prion exposure in mice. Neurosci Lett (2003) 1.09
Links between the pathology of Alzheimer's disease and vascular dementia. Neurochem Res (2004) 1.08
Immunomodulation targeting abnormal protein conformation reduces pathology in a mouse model of Alzheimer's disease. PLoS One (2010) 1.07
Circulating amyloid-beta peptide crosses the blood-brain barrier in aged monkeys and contributes to Alzheimer's disease lesions. Vascul Pharmacol (2002) 1.07
Differential degradation of amyloid beta genetic variants associated with hereditary dementia or stroke by insulin-degrading enzyme. J Biol Chem (2003) 1.07
A non-toxic ligand for voxel-based MRI analysis of plaques in AD transgenic mice. Neurobiol Aging (2007) 1.06
CpG oligodeoxynucleotide-enhanced humoral immune response and production of antibodies to prion protein PrPSc in mice immunized with 139A scrapie-associated fibrils. J Leukoc Biol (2007) 1.06
Brain clearance of Alzheimer's amyloid-beta40 in the squirrel monkey: a SPECT study in a primate model of cerebral amyloid angiopathy. J Drug Target (2002) 1.06
Depressive behavior in mice due to immune stimulation is accompanied by reduced neural activity in brain regions involved in positively motivated behavior. Biol Psychiatry (2006) 1.05
Immunological and anti-chaperone therapeutic approaches for Alzheimer disease. Brain Pathol (2005) 1.05
Relationship between cyclophilin a levels and matrix metalloproteinase 9 activity in cerebrospinal fluid of cognitively normal apolipoprotein e4 carriers and blood-brain barrier breakdown. JAMA Neurol (2013) 1.04
Complement activation in chromosome 13 dementias. Similarities with Alzheimer's disease. J Biol Chem (2002) 1.04
Evidence for cyclic diguanylate as a vaccine adjuvant with novel immunostimulatory activities. Cell Immunol (2012) 1.02
Prion protein is ubiquitinated after developing protease resistance in the brains of scrapie-infected mice. J Pathol (2004) 1.01
Plaque-associated overexpression of insulin-degrading enzyme in the cerebral cortex of aged transgenic tg2576 mice with Alzheimer pathology. J Neuropathol Exp Neurol (2006) 1.01